Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Imunexus Therapeutics Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active case is being processed by 1 distinct examiner, showing a singular focus for the portfolio's current prosecution. The data also shows that 1 distinct art unit is involved, which points to a specific regulatory focus within the pharmaceutical sector. Such concentration allows for a targeted legal approach but centralizes risk on a single examiner's decision regarding the 1 pending action.
The busiest examiner assigned to this portfolio is BRISTOL, LYNN ANNE, who is managing 1 pending office action. As the only examiner with an active case, BRISTOL, LYNN ANNE is responsible for the full scope of the portfolio's current pending workload. This arrangement requires the applicant to focus their immediate legal strategy on the requirements and precedents of the 1 art unit involved. The prosecution path is currently defined by this single examiner's review of the company's biotechnology filings, providing a clear but narrow route to potential patent issuance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18239052 | Multi-Specific Molecules | BRISTOL, LYNN ANNE | 28d |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18239052 | Multi-Specific Molecules | BRISTOL, LYNN ANNE | 1643 | §112 | Final Rejection | 28d | Pending | Aug 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImunexus Therapeutics Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Lynn Anne Bristol has the most, with 1 of Imunexus Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.